Your session is about to expire
← Back to Search
MGC018 + MGD019 for Solid Tumors
Study Summary
This trial is studying the effects of two drugs, MGC018 and lorigerlimab, when used in combination to treat patients with relapsed or refractory solid tumors, including metastatic prostate cancer, melanoma, pancreatic cancer, hepatocellular carcinoma, ovarian cancer, or renal cell carcinoma.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have an advanced solid tumor, such as prostate, melanoma, pancreatic, liver, ovarian, or kidney cancer.Your organs are working well, as shown in your lab test results.I have a history of Guillain-Barre syndrome, myasthenia gravis, or similar conditions.I have an advanced solid tumor such as prostate, melanoma, pancreatic, liver, ovarian, or kidney cancer.I have had a stem cell or organ transplant before.I haven't had treatment for another cancer, except for certain skin, prostate cancers, or early-stage cancers, in the last 2 years.I had severe side effects from previous immune therapy, but they are mostly resolved.I have not been treated with MGD009, enoblituzumab, or similar drugs targeting B7-H3 for cancer.I have fluid buildup in my chest or abdomen, but it's minimal.I can take care of myself and am up and about more than half of my waking hours.You are expected to live for at least 12 more weeks.I do not have any health or mental conditions that would stop me from following the treatment plan.I do not have serious heart, lung, vein, or stomach conditions.I have received treatments approved for my condition.I haven't had a serious infection needing treatment in the last week.I have HIV but my CD4+ count is above 300, my viral load is undetectable, and I've been on antiretroviral therapy for at least 4 weeks.I have mild to severe numbness, tingling, or pain in my hands or feet.I can provide a sample of my tumor tissue for testing.You are expected to live for at least 12 more weeks.There is a visible tumor that can be measured for assessment.
- Group 1: Cohort 3
- Group 2: Cohort 2
- Group 3: Cohort 5
- Group 4: Cohort 4
- Group 5: Cohort Expansion
- Group 6: Cohort -1
- Group 7: Cohort 1
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is the recruitment process still ongoing for this trial?
"Clinicaltrials.gov details that this clinical trial, which debuted on April 19th 2022, is currently enrolling participants. The most recent amendment to the experiment was made November 17th of the same year."
What is the cap on enrollees for this medical study?
"MacroGenics is spearheading this trial, which will require the recruitment of 258 eligible patients distributed across three sites. These are University of Pittsburgh Medical Center, Hillman Cancer Center in Pittsburgh, Pennsylvania and University of Virginia Comprehensive Cancer Centre in Charlottesville, Virginia."
What potential risks do people face when using MGC018?
"As this is a Phase 1 trial, with limited evidence supporting safety and efficacy, our team at Power gave MGC018 a rating of 1 out of 3 for its perceived risk."
At how many facilities is this clinical experiment being organized?
"Currently, participants can enrol in this trial at 7 distinct sites. Those located in Pittsburgh, Charlottesville and Los Angeles are available alongside 4 other locations. As the study requires travel to a clinical centre, it is best to choose one closeby for convenience."
Who else is applying?
What state do they live in?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
Why did patients apply to this trial?
Share this study with friends
Copy Link
Messenger